2010 SABCS Interview with Stacy Moulder, MD

Article

Dr. Stacy Moulder reviews her research on PARP inhibitors for hard-to-treat breast cancers.

In this interview, Stacy L. Moulder, MD, assistant professor of breast medical oncology at The University of Texas MD Anderson Cancer Center, talks about her research on PARP inhibitors for hard-to-treat breast cancers, such as triple-negative breast cancer, and the collaborative team that continues this line of research.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.